LBA9 IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC

Felip, Enriqueta; Vallières, Eric; Zhou, C.Z.; Wakelee, Heather A.; Bondarenko, Igor; Saito, Haruhiro; Ursol, Grigoriy; Kawaguchi, Koji; Liu, Y.; Levchenko, Evgeny; Kislov, Nikolay; Reck, Martin; Liersch, Rüediger; McNally, Virginia; Zhu, Qian; Ding, Beiying; Bennett, Elizabeth; Gitlitz, Barbara J.; Altorki, Nasser K.

doi:10.1016/j.annonc.2021.08.2120

Cited by 13 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, randomized clinical trial data support them as the standard treatment for patients with locally advanced or metastatic NSCLC, whether in monotherapy or in combination with chemotherapy [37]. More recently, PD-1/PD-L1 blockade has been shown to be also effective in the adjuvant and neo-adjuvant context in patients with early disease [38,39]. Although PD-L1 is far from being an ideal biomarker, the magnitude of benefit from PD-1/PD-L1 blockers in 1 3 monotherapy is related to the tumour expression of PD-L1 [38].…”

Section: Pd-l1mentioning

confidence: 99%

New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

et al. 2022

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) presents the greatest number of identified therapeutic targets, some of which have therapeutic utility. Currently, detecting EGFR, BRAF, KRAS and MET mutations, ALK, ROS1, NTRK and RET translocations, and PD-L1 expression in these patients is considered essential. The use of next-generation sequencing facilitates precise molecular diagnosis and allows the detection of other emerging mutations, such as the HER2 mutation and predictive biomarkers for immunotherapy responses. In this consensus, a group of experts in the diagnosis and treatment of NSCLC selected by the Spanish Society of Pathology and the Spanish Society of Medical Oncology have evaluated currently available information and propose a series of recommendations to optimize the detection and use of biomarkers in daily clinical practice.

show abstract

Section: Pd-l1mentioning

confidence: 99%

New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Additionally, for the first time the extent of the pathological response to a neoadjuvant ICI has been found to be an independent prognostic factor of OS and disease-free survival (DFS) in NSCLC [ 10 ]. What’s more, in IB-IIIA NSCLC of PD-L1 TC > 1%, adjunctive treatment with atezolizumab reduced the risk of disease recurrence or death by 34%, and the greatest DFS benefit was observed in a PD-L1 TC > 50% population [ 11 ]. However, in the CheckMate816 trial, pathologic complete response rates showed a consistent benefit in patients with different PD-L1 expressions [ 12 ].…”

Section: Tumor-related Biomarkersmentioning

confidence: 99%

The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer

Pan

Zeng

et al. 2022

Biomark Res

View full text Add to dashboard Cite

Immunotherapy has become the standard of care for non-small cell lung cancer (NSCLC), either in combination or monotherapy. However, there are still some patients who cannot benefit from it. Immunization strategies for NSCLC are based on the expression of PD-L1 on tumor cells and TMB, and although these indicators have a certain predictive effect, their predictive performance is not good. Therefore, clinicians must make adjustments to recognize markers. This is a review article that summarized immunotherapeutic biomarkers according to the “seed-soil-environment”, generalizes primary resistance to immunotherapy, and summarizes the integration of markers.

show abstract

“…While in the ctDNA-stage II-IIIA PD-L1-positive patients, the mDFS was NR (atezolizumab) versus 37.3 months (BSC), with an HR of 0.57 (95% CI: 0.36-0.90). ctDNA positivity after surgery was strongly prognostic for a greater risk of disease recurrence or death, and it was more prevalent with a higher disease state, increased nodal status, and EGFR-positive status (37). Based on the current research data, the MRD detection based on ctDNA has shown its excellence in predicting postoperative disease recurrence in early NSCLC patients and hence could benefit NSCLC patient management.…”

Section: Consensus 1: Pathological Diagnosis and Biomarker Testingmentioning

confidence: 78%

Expert consensus on perioperative treatment for non-small cell lung cancer

Duan¹,

Tan²,

Bi³

et al. 2022

Transl Lung Cancer Res

View full text Add to dashboard Cite

LBA9 IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC

Cited by 13 publications

References 0 publications

New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer

Expert consensus on perioperative treatment for non-small cell lung cancer

Contact Info

Product

Resources

About